Biomarin Pharmaceutical Inc (NAS:BMRN)
$ 67.2898 0.2198 (0.33%) Market Cap: 12.82 Bil Enterprise Value: 12.46 Bil PE Ratio: 40.29 PB Ratio: 2.37 GF Score: 69/100

Biomarin Pharmaceutical Inc R&D Day Transcript

Nov 14, 2019 / 01:00PM GMT
Release Date Price: $75.58 (-0.74%)
Henry J. Fuchs
BioMarin Pharmaceutical Inc. - President of Worldwide Research & Development

It's nice to see you all this morning. Thank you for the warm weather that you've offered to us Californians. I would -- can't hear you? That's okay, because I'm not saying anything. Guy walks into a bar.

Good morning, everybody. Thank you again for the warm welcome for BioMarin to New York City. Anyway, it's great to be here. My pleasure to kick off. I'm Hank Fuchs for those of you who don't know me, and I -- you see who I am and what my title is. And it's my pleasure to introduce the day. So let's see, do I control the slides, Traci? Yes. Safe harbor statement, public company, we're going to say some things, rely on our filings.

I just had my 10-year anniversary at the company. And so I've been here kind of like for half of the life of the company. And it's been -- I've been reflecting on what Emil started and I've been able to build on with great good fortune. And it's really been a privilege to deliver medicines to primarily children who have few, if any, options for therapy. And along

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot